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Introduction: Lung cancer in never-smokers ranks among the 10 
most common causes of death due to cancer worldwide and in the 
United States. However, it is unknown whether never-smokers at ele-
vated risk for developing lung cancer may benefit from lung cancer 
screening.
Methods: The MIcrosimulation SCreening ANalysis (MISCAN)-
Lung microsimulation model was used to assess the effects of lung 
cancer screening for simulated cohorts of never-smokers at different 
levels of relative risk (RR) for lung cancer compared with never-
smokers at average risk. The benefits and harms of screening were 
estimated for each cohort and compared with those of a cohort of 
ever-smokers eligible for lung cancer screening according to the 
United States Preventive Services Task Force (USPSTF) criteria.
Results: The relative lung cancer mortality reduction in never-smok-
ers was higher than the USPSTF eligible cohort (37% compared 
with 32%). However, the number of life-years gained per lung can-
cer death averted was lower (10.4 compared with 11.9) and the pro-
portion of overdiagnosed cancers was higher (9.6% compared with 
8.4%) for never-smokers compared with the USPSTF eligible cohort, 
as never-smokers are diagnosed at a later age. The estimated number 
of screens per lung cancer death averted ranged from 6162 for never-
smokers at average risk to 151 for never-smokers with an RR of 35 
compared with 353 for the USPSTF eligible cohort.
Conclusions: Never-smokers with RRs of 15 to 35 have similar to 
better trade-offs between benefits and harms compared with ever-
smokers recommended for lung cancer screening by the USPSTF 
guidelines. For most never-smokers, lung cancer screening is not 
beneficial.
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Although smoking is considered a main risk factor for developing lung cancer, 10% to 25% of all lung cancers 
occur in never-smokers.1,2 Lung cancer in never-smokers is a 
significant public health problem, as it ranks among the 10 
most common causes of death due to cancer worldwide and in 
the United States.2–4
The results of the National Lung Screening Trial (NLST) 
have indicated that lung cancer mortality can be reduced by 
screening ever-smokers with computed tomography (CT).5 
The United States Preventive Services Task Force (USPSTF) 
recently published the recommendation to implement annual 
lung cancer screening for ever-smokers aged 55 to 80 years 
who have smoked at least 30 pack-years and, if quit smoking, 
quit less than 15 years ago.6 Other organizations have recom-
mended screening using the NLST eligibility criteria or varia-
tions thereof.7–9 To our knowledge, no organization currently 
recommends lung cancer screening for never-smokers.
Some lung cancer screening studies have included 
never-smokers, but these studies used chest radiography or 
were single-arm studies.10–12 A survey on attitudes toward lung 
cancer screening in the United States showed that a large pro-
portion of never-smokers were willing to consider lung cancer 
screening, even though few believed that they were at risk for 
developing lung cancer.13
In addition to tobacco smoking, various risk factors 
for developing lung cancer have been identified for ever- and 
never-smokers, such as environmental tobacco smoke (e.g., 
“second-hand smoking”), exposure to carcinogens (e.g., 
asbestos, radon gas, and ionizing radiation), and genetic sus-
ceptibility.3,14–16 A number of risk models incorporate these 
and other risk factors to identify ever- and never-smokers at 
elevated levels of risk.17–21 Recent studies have identified sub-
populations within the NLST who were at a higher level of 
risk for developing lung cancer compared with the average 
population of the trial.20,22,23 Screening was more effective for 
these subpopulations, which indicates that screening recom-
mendations based on an individual’s risk could lead to more 
effective screening programs.20,22,23 Therefore, some research-
ers argue that lung cancer screening may be recommended for 
never-smokers, provided that they have a high risk for devel-
oping lung cancer.24
However, the long-term benefits and harms of imple-
menting a lung cancer screening program for never-smokers 
are unknown. The USPSTF recommendations were in part 
based on modeling analyses, which investigated the trade-offs 
between the long-term benefits and harms of different screen-
ing policies for ever-smokers.25 This study aims to investigate 
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the trade-offs between the benefits and harms of lung cancer 
screening for never-smokers at different levels of risk.
MATERIALS AND METHODS
MISCAN-Lung
The MIcrosimulation SCreening ANalysis (MISCAN)-
Lung model is used in this investigation. MISCAN-Lung has 
been calibrated to the NLST, the Prostate, Lung, Colorectal 
and Ovarian Cancer Screening trial (PLCO), and data from 
the Surveillance, Epidemiology and End Results (SEER) 
Program, from which it derived information on the preclinical 
duration of lung cancer and CT screening effectiveness.26,27 
Lung cancer incidence and mortality in never-smokers in the 
PLCO were among the calibration targets of the model.26,27 
MISCAN-Lung aided in informing the USPSTF on their rec-
ommendations for lung cancer screening.25,28
Histologic Types
There are indications that smoking behavior affects not 
only a person’s risk of developing lung cancer but also the 
histologic type that develops.29,30 This suggests that the distri-
bution of histological types of lung cancer in never-smokers 
may differ from ever-smokers. Subramanian and Govindan16 
provided an overview of the distribution of histological types 
of lung cancer in never-smokers across different studies. This 
overview was used to derive the distribution of histological 
types of lung cancer in never-smokers for this investigation, 
shown in Table 1.16 To our knowledge, little information is 
available on differences in the distribution of histological types 
of lung cancer in never-smokers between sexes. Therefore, we 
assumed that the distribution of histological types of lung can-
cer in never-smokers did not differ by sex.
Lung Cancer Survival
It has been suggested that never-smokers may have a 
better response to certain treatments compared with ever-
smokers, such as treatment with epidermal growth factor 
receptor inhibitors, which could lead to differences in sur-
vival.31,32 Some studies suggest that never-smokers have a 
better survival compared with ever-smokers, whereas other 
studies indicate that no significant differences in survival 
exist.33–36 To our knowledge, no study provides detailed 
data on lung cancer survival for never-smokers by stage, 
histology, and sex.33–36 Therefore, survival data from SEER 
were used, which provides detailed information on survival 
by stage, histology, and sex for ever- and never-smokers 
combined.37
Lung Carcinogenesis
MISCAN-Lung uses the two-stage clonal expansion 
model (TSCE) to estimate a person’s risk of developing lung 
cancer as a function of age and smoking history.26,27,38,39 The 
TSCE has been used to investigate the age-specific incidence of 
lung cancer in never-smokers previously.14,39,40 To assess whether 
MISCAN-Lung is suitable for investigating the effectiveness of 
lung cancer screening for never-smokers, the estimated age-
group–specific mortality rates of lung cancer in never-smokers 
were compared with those reported by Thun et al.41
Considered Levels of Relative Risk
If lung cancer screening is to be considered for never-
smokers, eligible individuals will need to be identified, for 
example, through the application of risk models. To our 
knowledge, the following lung cancer risk models consider 
never-smokers: the Spitz, PLCOm2011, PLCOm2014, and the 
Liverpool Lung Project (LLP) models.17–20 The Spitz model 
incorporates environmental tobacco smoke exposure (odds 
ratio [OR], 1.80; 95% confidence interval [CI], 1.20–2.69)) 
and a family history of any cancer in two or more first-degree 
relatives (OR, 2.00; 95% CI, 1.39–2.90).18 Spitz et al18 noted 
that the ORs of these variables closely approximated the rela-
tive risks (RRs). Thus, the Spitz model considers RRs up to 3.6. 
Recently, this model was extended to incorporate micronuclei 
in binucleated cells (BN-MN) (OR 16.72 per unit increase; 
95% CI, 9.01–31.02) alongside environmental tobacco smoke 
exposure (OR, 1.12; 95% CI, 0.47–2.68) and a family history 
of cancer in two or more first-degree relatives (OR, 1.06; 95% 
CI, 0.47–2.43).21 The average difference in BN-MN between 
cases and controls in the model’s development and validation 
data sets was 1.78 to 1.79 units.21 Assuming the ORs of the 
model variables closely approximate the RRs and an increase 
of 1.80 units of BN-MN compared with a never-smoker at 
average risk is considered, the model considers RRs up to at 
least 35.73 for never-smokers.
The PLCOm2011 model was the first model based on 
data from PLCO to provide risk estimates for never-smokers.17 
Recently, an updated version of this model (PLCOm2014) 
was published that incorporates five risk factors (excluding 
age and race) for never-smokers: education (OR 0.92 per one 
of six levels change; 95% CI, 0.87–0.96), body mass index 
(BMI) (OR 0.97 per one unit change; 95% CI, 0.95–0.99), 
TABLE 1.  Histological Types Considered in MISCAN-Lung
Histological Types Considered in 
MISCAN-Lung
Proportions Considered in  
Never-Smokers (Both Sexes)
Proportions Considered in 
Ever-Smokers (Men)
Proportions Considered in 
Ever-Smokers (Women)
Adenocarcinoma/large cell carcinoma/ 
bronchioloalveolar carcinoma
66.68% 41.01% 50.33%
Squamous cell carcinoma 13.68% 25.22% 15.78%
Small-cell carcinoma 2.53% 13.75% 13.26%
Other non–small-cell carcinoma 17.12% 20.02% 20.63%
MISCAN, Microsimulation Screening Analysis model.
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chronic obstructive pulmonary disease (OR, 1.41; 95% CI, 
1.15–1.73), a personal history of cancer (OR, 1.62; 95% CI, 
1.22–2.16), and a family history of lung cancer (OR, 1.80; 
95% CI, 1.48–2.18).20 The calculator provided by the authors 
was used to verify that the ORs closely approximate the RRs 
(available at http://www.brocku.ca/lung-cancer-risk-calcula-
tor). A BMI of 18 is the lowest for which the model is valid 
and assuming the base BMI and education levels are similar 
to those in the PLCOm2012 model (a BMI of 27 and “some 
college education”), implies that the PLCOm2014 model con-
siders RRs up to 6.98 (disregarding age and race).20,23
The LLP model incorporates four risk factors for never-
smokers: a history of pneumonia (OR, 1.83; 95% CI, 1.26–
2.64), asbestos exposure (OR, 1.89; 95% CI, 1.35–2.62), a 
history of cancer (OR, 1.96; 95% CI, 1.22–3.14), and a fam-
ily history of lung cancer (OR, 2.02 for age of onset <60; 
95% CI, 1.18–3.45; and 1.18 for age of onset ≥60; 95% CI, 
0.79–1.76).19 The model was replicated in R software (version 
3.0.1) and analyses indicate that the ORs of the risk factors 
closely approximate the RRs. Thus, the LLP model considers 
RRs up to 13.69.
Therefore, cohorts of never-smokers with the following 
levels of RR will be simulated: 1, 2, 5, 10, 15, 20, and 35. For 
cohorts with RRs higher than 1, the hazard function of the 
TSCE at each age was multiplied by the considered level of 
RR.25 In addition, a “USPSTF eligible” cohort is simulated 
composed of individuals who would be eligible for at least one 
screening at some point in their life according to the USPSTF 
recommendations. The Smoking History Generator devel-
oped by the National Cancer Institute was used to generate 
the probability of death from causes other than lung cancer by 
smoking behavior (including never smoking).42–44
Considered Screening Programs, 
Benefits, and Harms
The investigated cohorts are assumed to be born in 
1950 and followed from ages 45 to 90 years, similar to de 
Koning et al.25 To allow comparison with the screening policy 
recommended by the USPSTF, never-smokers are assumed to 
be screened annually from ages 55 to 80 years with a per-
fect adherence to screening. The investigated benefits and 
harms of lung cancer screening include the relative reduction 
in lung cancer mortality, the number of life-years gained, and 
overdiagnosis.
RESULTS
The age-group–specific lung cancer mortality 
rates for never-smoking men and women estimated by 
MISCAN-Lung were compared with those reported by 
Thun et al41 (Table S13 in their report), in Figure 1A and 
B, respectively. Overall, the model reproduced the reported 
FIGURE 1. A, Observed and estimated lung can-
cer death rates in never-smoking men. Adapted 
from Thun et al.41 Error bars denote 95% confi-
dence intervals for the incidence rate difference. 
B, Observed and estimated lung cancer death 
rates in never-smoking women. Adapted from 
Thun et al.41 Error bars denote 95% confidence 
intervals for the incidence rate difference.
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age-group–specific lung cancer mortality rates well for both 
sexes but somewhat overestimated the lung cancer mortality 
rate for ages 75 to 79 years.
Table 2 shows the benefits of lung cancer screening 
for the investigated cohorts. The proportion of lung cancers 
detected at an early stage was higher for never-smokers com-
pared with the USPSTF eligible cohort (65.8–65.9% of all 
cases compared with 59.4%). This may be a result of the 
higher proportion of adenocarcinomas in never-smokers (see 
Table 1), which have a longer preclinical sojourn time and 
are more likely to be detected at an early stage by CT screen-
ing compared with other histologies.26 As a result of the 
larger proportion of lung cancers detected at an early stage, 
the relative reduction in lung cancer mortality was higher for 
never-smokers compared with the USPSTF eligible cohort: 
37.0% to 37.3% compared with 32.7%. However, the num-
ber of lung cancer deaths averted (per 100,000) was lower 
for most cohorts of never-smokers, ranging from 354 deaths 
averted for never-smokers at average risk to 12,509 for 
never-smokers with an RR of 35 compared with 4305 for the 
USPSTF eligible cohort. The same holds for the number of 
life-years gained (per 100,000), which ranged from 3669 for 
never-smokers at average risk to 129,509 for never-smokers 
with an RR of 35 compared with 51,035 for the USPSTF 
eligible cohort.
The number of lung cancer deaths averted and life-
years gained for never-smokers with an RR of 15 were higher 
compared with the USPSTF cohort. However, because of 
the high number of screens, the number of screens per life-
year gained and the number of screens per lung cancer death 
averted were still higher compared with the USPSTF cohort. 
However, screening never-smokers with an RR of 20 leads to 
a slightly lower number of screens per life-year gained and a 
much lower number of screens per lung cancer death averted 
compared with the USPSTF cohort.
Table 3 shows the harms of lung cancer screening 
for the investigated cohorts. The number of screens (per 
100,000) was much greater for the USPSTF eligible and 
never-smoker cohorts compared with the 1950 cohort exam-
ined in de Koning et al,25 as in the latter cohort only 19.3% of 
the cohort received at least one screen. The number of screens 
was higher for the never-smoker cohorts compared with the 
USPSTF eligible cohort: approximately 1.8 to 2.1 million 
screens compared with 1.5 million screens. This is because 
of two reasons: first, never-smokers live longer compared 
with ever-smokers and will be able to attend more screenings 
during their lifetime.43,45 Second, the USPSTF criteria indi-
cate that ever-smokers may not be eligible for screening at 
the earliest starting age, as some current, continuing smokers 
may not reach the minimum number of pack-years at age 55 
TABLE 2.  Benefits of Screening
Scenario
Lung Cancers 
Detected at an 
Early Stage  
(Stage I–II) (%)
Lung  
Cancer  
Mortality 
Reduction (%)
Absolute Number 
of Lung Cancer 
Deaths Averted 
per 100,000
Life-Years  
Gained per 
100,000
Life-Years  
Gained per Lung 
Cancer Death 
Averted
Screens  
per  
Life-Year 
Gained
Screens  
per Lung 
Cancer Death 
Averted
USPSTF (ever eligible only) 59.4 32.7 4,305 51,035 11.9 30 353
Never-smokers at average risk 65.8 37.1 354 3,669 10.4 594 6,162
Never-smokers at two times average risk 65.9 37.0 706 7,332 10.4 296 3,075
Never-smokers at five times average risk 65.8 37.0 1,764 18,359 10.4 117 1,216
Never-smokers at 10 times average risk 65.8 37.1 3,541 36,809 10.4 57 593
Never-smokers at 15 times average risk 65.8 37.1 5,322 55,247 10.4 37 387
Never-smokers at 20 times average risk 65.8 37.1 7,118 73,892 10.4 27 283
Never-smokers at 35 times average risk 65.9 37.3 12,509 129,786 10.4 15 151
USPSTF, United States Preventive Services Task Force.
TABLE 3.  Harms of Screening
Scenario
Screens per 
100,000
CT Examinations  
per 100,000  
(Includes Screenings)
Average Screening 
Examinations per 
Person Screened
Percentage of  
Lung Cancers  
Overdiagnosed
Percentage of  
Screen-Detected 
Lung Cancers  
Overdiagnosed
USPSTF (ever eligible only) 1,520,632 1,776,046 16.2 4.6 8.4
Never-smokers at average risk 2,179,173 2,544,605 22.5 5.2 9.5
Never-smokers at two times average risk 2,170,544 2,534,532 22.5 5.2 9.6
Never-smokers at five times average risk 2,144,601 2,504,249 22.2 5.3 9.6
Never-smokers at 10 times average risk 2,101,248 2,453,645 21.9 5.3 9.6
Never-smokers at 15 times average risk 2,057,745 2,402,865 21.5 5.3 9.6
Never-smokers at 20 times average risk 2,014,118 2,351,940 21.1 5.3 9.6
Never-smokers at 35 times average risk 1,882,721 2,198,562 19.9 5.3 9.6
USPSTF, United States Preventive Services Task Force.
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but at a later age. In addition, eligible former smokers may 
not complete the full screening program because of becoming 
ineligible by reaching the maximum years since cessation. As 
a result, the average number of screening examinations per 
person screened was higher for the cohorts of never-smokers 
compared with the USPSTF eligible cohort (20–22 compared 
with 16). As the never-smoker cohorts receive a higher num-
ber of screening examinations and are diagnosed at a later 
age (when no screening occurs), the proportion of overdiag-
nosis was higher compared with the USPSTF eligible cohort 
(9.5–9.6% of all screen-detected cases compared with 8.4%).
DISCUSSION
Suggestions to recommend lung cancer screening 
based on an individual’s risk and the growing awareness of 
lung cancer in never-smokers have raised the question of 
whether never-smokers at high risk for lung cancer should be 
screened.2–4,12,14,20,23,30,33,35,41,46 Our study is the first to provide 
indications whether never-smokers may benefit from lung 
cancer screening through quantifying the benefits and harms 
of screening never-smokers at different levels of risk.
Screening never-smokers at average risk or an RR of 2 
compared with average risk has unfavorable trade-offs between 
benefits and harms, requiring 3000 to 6000 screens to prevent 
one death. However, the trade-off for never-smokers with an 
RR of 5 is more favorable than breast cancer screening: 1216 
screens per death averted compared with 1558 (Model E in 
Mandelblatt et al47); however, the number of screens per life-
year gained is less favorable: 117 compared with 91. Never-
smokers with an RR of 10 have more favorable trade-offs in 
deaths prevented and life-years gained per screen compared 
with breast cancer screening but less favorable compared with 
ever-smokers for whom the USPSTF recommends screen-
ing.25,47 However, never-smokers with an RR of 15 to 35 have 
similar to more favorable trade-offs between the benefits and 
the harms compared with smokers for whom the USPSTF rec-
ommends screening.
Lung cancer screening for never-smokers may lead to a 
higher relative reduction in lung cancer mortality compared 
with screening ever-smokers. However, although the cohorts 
of never-smokers have a higher relative reduction in lung can-
cer mortality compared with the USPSTF eligible cohort, the 
increase in number of life-years gained is less than one would 
anticipate. For example, the number of lung cancer deaths 
averted for never-smokers with an RR of 15 was 23.62% 
higher compared with the USPSTF eligible cohort, whereas 
the number of life-years gained was only 8.25% higher (Table 
2). This can be explained by the lower number of life-years 
gained per lung cancer death averted, which was 11.9 years 
for the USPSTF eligible cohort compared with 10.4 for the 
never-smoker cohorts. This may seem counterintuitive, as 
ever-smokers have a higher all-cause mortality compared 
with never-smokers but can be explained through the differ-
ences in the average age of lung cancer diagnosis and average 
age of death between these groups.43,45 Supplementary Table 1 
(in Supplemental Digital Content, http://links.lww.com/JTO/
A851) shows the average age of lung cancer diagnosis (given 
that the cancer is diagnosed after age 45) and the average age 
of death (given that the person is alive at age 45 years) for the 
investigated cohorts. Supplementary Table 1 (in Supplemental 
Digital Content, http://links.lww.com/JTO/A851) indicates 
that persons in the USPSTF eligible cohort die younger com-
pared with never-smokers because of the detrimental effects 
of smoking.43,45 However, because of the carcinogenic effects 
of smoking, patients in the USPSTF eligible cohort developed 
lung cancer at a younger age compared with never-smokers. 
In addition, the high proportion of adenocarcinoma in never-
smokers, which have a longer preclinical sojourn time com-
pared with other histologies, may further contribute to the 
later age of diagnosis.26
Our investigation has some limitations. We assume 
that the preclinical duration of lung cancer in never-smokers 
is similar to that of ever-smokers, whereas there are indica-
tions that lung cancer biology may differ in never-smokers.3 
However, although the carcinogenesis process may differ in 
never-smokers, to our knowledge, there are no indications 
that differences in the preclinical duration of lung cancer exist 
between never- and ever-smokers.3
Another limitation is that the investigated levels of RR 
are assumed to be constant over a person’s life. Although the 
elevation in risk may be constant over a person’s life for some 
risk factors, such as genetic susceptibility, this may not be the 
case for risk factors such as asbestos or radon exposure.3,14,16 
However, the benefits and harms of screening never-smokers 
at specific levels of RR are more easily interpreted by assum-
ing that the RR is constant over a person’s lifetime.
Finally, although our research indicates at what level 
of risk for developing lung cancer never-smokers could ben-
efit from lung cancer screening, our findings are based on 
model-based extrapolations. Further research is needed to 
accurately identify never-smokers at high risk for develop-
ing lung cancer, which would allow us to further validate 
our findings. However, although a number of risk factors for 
developing lung cancer in never-smokers have been iden-
tified, the etiology of lung cancer in never-smokers is not 
well understood.3,14–16,46 Although lung cancer risk models 
for never-smokers exist, the performance of the majority of 
these models is limited.17–19,48
This is further demonstrated by comparing the risk of 
developing lung cancer for an average 67-year-old (the age 
between the USPSTF recommended screening ages of 55–
80 years) never-smoker (by sex) for different time frames 
in MISCAN-Lung (Supplementary Table 2, Supplemental 
Digital Content, http://links.lww.com/JTO/A851) with those 
of the investigated risk models (Supplementary Table 3 in 
Supplemental Digital Content, http://links.lww.com/JTO/
A851). Supplementary Table 3 (in Supplemental Digital 
Content, http://links.lww.com/JTO/A851) indicates that 
the investigated lung cancer risk models for never-smokers 
generally predict higher lung cancer risks compared with 
MISCAN-Lung. However, the age-group–specific lung can-
cer mortality rates for never-smoking men and women esti-
mated by MISCAN-Lung are comparable with those reported 
by Thun et al41 (Table S13 in their report). This indicates that 
the majority of lung cancer risk models may overestimate the 
risk of lung cancer for never-smokers.
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Finally, the proportion of never-smokers with RRs of 
15 compared with never-smokers at average risk is uncertain 
as information on many risk factors (and the joint distribu-
tion thereof) is scarcely available at the population level. The 
application of the PLCOm2014 model to the PLCO data set 
and the application of the LLP model for recruiting partici-
pants for the UK Lung Cancer Screening Trial (UKLS) may 
currently provide the best information on the expected levels 
of risk for never-smokers.20,49
The PLCOm2014 model suggests that the maximum 
observed risk in 65,711 never-smokers in the PLCO was 
1.47% over a 6-year period.20 A white never-smoker attain-
ing the highest level of RR (6.98, disregarding age and race) 
would not reach this level of risk until age 73 years (veri-
fied using the calculator provided by the authors, available 
at http://www.brocku.ca/lung-cancer-risk-calculator). The 
theoretical maximum possible 6-year risk of lung cancer for 
never-smokers in the PLCOm2014 model is 3.5%; however, 
the necessary combination of risk factors to achieve this level 
of risk is expected to be rare.20
The LLP model was used to recruit participants for the 
UKLS trial, including never-smokers.49 Only four (0.04% 
of 10,697) never-smokers had a high LLP risk (a risk of 5% 
or higher over a 5-year period) and all were aged at least 73 
years.49 Analyses using the model (replicated in R software) 
suggest that both men and women can only achieve this abso-
lute level of risk at this age at the highest level of RR (13.69).
In conclusion, this study is the first to investigate the 
long-term benefits and harms of lung cancer screening for 
never-smokers. Screening never-smokers at high levels 
of elevated risk for developing lung cancer (RRs of 15 or 
higher compared with average risk) is indicated to have 
similar or better trade-offs between benefits and harms as 
the population for which the USPSTF recommends screen-
ing. However, most lung cancer risk models for never-
smokers consider RRs of lower than 15 for never-smokers 
at elevated risk compared with never-smokers at average 
risk. In addition, the majority of lung cancer risk models for 
never-smokers may overestimate the average risk of never-
smokers. Applications of lung cancer risk models to popu-
lations of never-smokers suggest that few never-smokers 
attain high levels of risk.20,49 Thus, few never-smokers are 
expected to attain RRs of 15 compared with never-smokers 
at average risk. Therefore, for most never-smokers, lung 
cancer screening is not beneficial.
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